The Challenges of Chronic Urticaria Part 1: Epidemiology, Immunopathogenesis, Comorbidities, Quality of Life, and Management

Overview

Journal World Allergy Organ J

Specialty Allergy & Immunology

Date 2021 Jul 5

PMID 34221215

Citations 29

Authors

Mario Sanchez-Borges

Ignacio J Ansotegui

Ilaria Baiardini

Jonathan Bernstein

Giorgio Walter Canonica

Motohiro Ebisawa

Maximiliano Gomez

Sandra Nora Gonzalez-Diaz

Bryan Martin

Mario Morais-Almeida

Jose Antonio Ortega Martell

Affiliations

Soon will be listed here.

Abstract

This is Part 1 of an updated follow-up review of a World Allergy Organization (WAO) position paper published in 2012 on the diagnosis and treatment of urticaria and angioedema. Since 2012, there have been advances in the understanding of the pathogenesis of chronic urticaria, and greater experience with the use of biologics, such as omalizumab, in patients with severe refractory disease. For these reasons, the WAO decided to initiate an update targeted to general practitioners around the world, incorporating the most recent information on epidemiology, immunopathogenesis, comorbidities, quality of life, clinical case presentations, and the management of chronic spontaneous and chronic inducible urticaria, including urticaria in special situations such as childhood and pregnancy. A special task force of WAO experts was invited to write the different sections of the manuscript, and the final document was approved by the WAO Board of Directors. This paper is not intended to be a substitute for current national and international guidelines on the management of urticaria and angioedema but to provide an updated, simplified guidance for physicians around the world who manage patients with this common ailment.

Citing Articles

Effect of combining histaglobulin with antihistamines in patients with chronic spontaneous urticaria in a tertiary care hospital setting- a randomized trial.

Ramanna K, Sumanth T, Konda D, Eerike M, Kalaiselvan S, Elangovan C Arch Dermatol Res. 2025; 317(1):516.

PMID: 40024926 DOI: 10.1007/s00403-025-04045-w.

Evaluation of Bilastine's Efficacy and Safety in Treating Chronic Idiopathic Urticaria in Iraqi Patients.

Abdul-Reda F, Al-Zobaidy M Med J Islam Repub Iran. 2025; 38:121.

PMID: 39968464 PMC: 11835394. DOI: 10.47176/mjiri.38.121.

Relationship between cigarette smoking and chronic spontaneous urticaria. Is there a difference in neutrophil-lymphocyte ratio?.

Moos L, Chodak W, Czyczerska M, Garbino K, Gleba O, Snietka B Postepy Dermatol Alergol. 2025; 41(6):617-621.

PMID: 39877102 PMC: 11770574. DOI: 10.5114/ada.2024.143640.

Phototherapy as an alternative in the treatment of chronic spontaneous urticaria.

Giustozzi M, Torre A, Ritchie C, Parisi C Front Allergy. 2024; 5:1468983.

PMID: 39640431 PMC: 11617558. DOI: 10.3389/falgy.2024.1468983.

Jujube Oxymel for the Treatment of Chronic Spontaneous Urticaria: Efficacy and Safety.

Shirazi M, Goodarzi A, Ghobadi A, Eghbalian F Adv Biomed Res. 2024; 13:91.

PMID: 39512402 PMC: 11542698. DOI: 10.4103/abr.abr_426_23.

References

Guevara-Gutierrez E, Bonilla-Lopez S, Hernandez-Arana S, Tlacuilo-Parra A . Safety and efficacy of cetirizine versus cetirizine plus ranitidine in chronic urticaria: Double-blind randomized placebo-controlled study. J Dermatolog Treat. 2015; 26(6):548-50. DOI: 10.3109/09546634.2015.1025031. View

Baiardini I, Braido F, Bindslev-Jensen C, Bousquet P, Brzoza Z, Canonica G . Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper. Allergy. 2011; 66(7):840-4. DOI: 10.1111/j.1398-9995.2011.02580.x. View

Brzoza Z, Nabrdalik K, Moos L, Kwiendacz H, Badura-Brzoza K, Jarolim H . Chronic Spontaneous Urticaria and Type 1 Diabetes Mellitus-Does Quality of Life Impairment Always Reflect Health Danger?. J Clin Med. 2020; 9(8). PMC: 7465008. DOI: 10.3390/jcm9082505. View

Balp M, Weller K, Carboni V, Chirilov A, Papavassilis C, Severin T . Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients. Pediatr Allergy Immunol. 2018; 29(6):630-636. DOI: 10.1111/pai.12910. View

Pezzolo E, Peroni A, Gisondi P, Girolomoni G . Heat urticaria: a revision of published cases with an update on classification and management. Br J Dermatol. 2016; 175(3):473-8. DOI: 10.1111/bjd.14543. View

Savic S, Leeman L, El-Shanawany T, Ellis R, Gach J, Marinho S . Chronic urticaria in the real-life clinical practice setting in the UK: results from the noninterventional multicentre AWARE study. Clin Exp Dermatol. 2020; 45(8):1003-1010. DOI: 10.1111/ced.14230. View

Baiardini I, Giardini A, Pasquali M, Dignetti P, Guerra L, Specchia C . Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy. 2003; 58(7):621-3. DOI: 10.1034/j.1398-9995.2003.00091.x. View

Andrews J, Guyatt G, Oxman A, Alderson P, Dahm P, Falck-Ytter Y . GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013; 66(7):719-25. DOI: 10.1016/j.jclinepi.2012.03.013. View

Konstantinou G, Konstantinou G . Psychiatric comorbidity in chronic urticaria patients: a systematic review and meta-analysis. Clin Transl Allergy. 2019; 9:42. PMC: 6706894. DOI: 10.1186/s13601-019-0278-3. View

10.

Gaig P, Olona M, Munoz Lejarazu D, Caballero M, Dominguez F, Echechipia S . Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol. 2004; 14(3):214-20. View

11.

Kang M, Kim H, Kim H, Park Y . The impact of chronic idiopathic urticaria on quality of life in korean patients. Ann Dermatol. 2010; 21(3):226-9. PMC: 2861226. DOI: 10.5021/ad.2009.21.3.226. View

12.

DeLong L, Culler S, Saini S, Beck L, Chen S . Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol. 2008; 144(1):35-9. DOI: 10.1001/archdermatol.2007.5. View

13.

Staubach P, Eckhardt-Henn A, Dechene M, Vonend A, Metz M, Magerl M . Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol. 2006; 154(2):294-8. DOI: 10.1111/j.1365-2133.2005.06976.x. View

14.

Thoma A, Eaves 3rd F . A brief history of evidence-based medicine (EBM) and the contributions of Dr David Sackett. Aesthet Surg J. 2015; 35(8):NP261-3. DOI: 10.1093/asj/sjv130. View

15.

Guillet G, Becherel P, Pralong P, Delbarre M, Outtas O, Martin L . The burden of chronic urticaria: French baseline data from the international real-life AWARE study. Eur J Dermatol. 2019; 29(1):49-54. DOI: 10.1684/ejd.2018.3495. View

16.

Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M . Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol. 2010; 35(8):869-73. DOI: 10.1111/j.1365-2230.2010.03840.x. View

17.

Gomez R, Jares E, Canonica G, Baiardini I, Passalacqua G, Sanchez Borges M . Why a registry of Chronic Urticaria (CUR) is needed. World Allergy Organ J. 2017; 10(1):16. PMC: 5433157. DOI: 10.1186/s40413-017-0147-2. View

18.

Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerra L, Compalati E . A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy. 2005; 60(8):1073-8. DOI: 10.1111/j.1398-9995.2005.00833.x. View

19.

Tzur Bitan D, Berzin D, Cohen A . The association of chronic spontaneous urticaria (CSU) with anxiety and depression: a nationwide cohort study. Arch Dermatol Res. 2020; 313(1):33-39. DOI: 10.1007/s00403-020-02064-3. View

20.

Maurer M, Abuzakouk M, Berard F, Canonica W, Oude Elberink H, Gimenez-Arnau A . The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU. Allergy. 2017; 72(12):2005-2016. PMC: 5724512. DOI: 10.1111/all.13209. View